Biotechnology is one of the key frontiers in the war against emerging health threats, such as viruses and drug-resistant bacterial infections. Furthermore, it is one of the few industries that make up the health care sector that focuses on defeating illnesses and diseases before they are able to spread and cause global disaster. Without the continued rigorous research and development of new medications to fight off the next potential pandemic, we risk repeating deadly periods of our past such as the “Black Death.”
According to Grand View Research, Inc., the global biotechnology market is forecast to reach $727.10 billion by 2025. The market research firm sees the growth in biotech being driven by regenerative medicines and genetics in diagnostics. Technological advances, particularly artificial intelligence, are expected to be a driving force behind diagnosis and understanding each individual’s particular health case. Grand View Research sees very supportive government actions and policies on biotechnology, which will continue to support growth within the industry.
As biotechnology continues to be an increasingly important tool in the fight against severe ailments, Innovest Global, Inc. (OTC Pink: IVST) is one company that stands to benefit.
IVST: Launching New Biotechnology and Health Sciences Division This Spring
Innovest Global, Inc. (OTC Pink: IVST) recently announced that it has formed a new biotechnology and health sciences subsidiary to go along with its commercial and industrial businesses. The new division will officially launch this Spring and will be led by world renowned neuroscientist, Dr. Dwain Morris-Irvin.
“Dr. Morris-Irvin is an active participant in many Biotechnology and Health Science endeavors, and is an expert including patent generation in such areas as treatments for Parkinson’s, brain cancer, and even cosmetic application of advanced bioscience,” said Dan Martin, CEO of Innovest Global.
He also trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. Dr. Morris-Irvin received his PhD from UCLA School of Medicine, and Masters in Public Health from UCLA School of Public Health.
Needless to say, Dr. Dwain Morris-Irvin is a heavy-hitter in the biotechnology and life sciences industry and is the perfect individual to lead Innovest’s new biotech division. More details are expected in the next several weeks, but the new division will be headquartered in Los Angeles, CA.
“Dr. Morris-Irvin has a unique combination of subject matter expertise, experience, and business acumen that make him a perfect leader for this division,” said Innovest CEO, Dan Martin. “And he’s one of the most respected professionals and best people you could ever have the pleasure to know. We expect this division to result in ownership of meaningful intellectual property and other progress, without the significant capital costs of traditional biotech initiatives. His relationships, plans, and creativity tell me we will have an exciting path ahead that we are well equipped to execute, and I am thrilled to get started on it with him at the helm.”
IVST: Two Recent Meetings With U.S. Congressional Representative In Ohio
Innovest Global, Inc. (OTC Pink: IVST) recently announced on its official Twitter page that it has just met with the U.S. Congressman in Innovest’s district in Ohio for the second time in under a month. The first meeting took place in mid-February, while the congressman returning at the end of the month for another discussion and photo
opp. As the Twitter post mentions, the discussions mostly pertained to Trump tax cut benefits and other legislative matters. However, you do not see many other congressional representatives visiting Pink Sheet companies. This shows the company continues on the right track, which is catching people’s attention.
In other recent news, Innovest Global, Inc. (OTC Pink: IVST) announced it has generated revenues of $388,000, through the halfway point of the first quarter 2018. This beat management’s estimates by a resounding 55%. Innovest Global, Inc.’s (OTC Pink: IVST) energy, durable goods, and call center subsidiaries have been boosting baseline sales. Overall, the company estimates baseline revenue of $500,000 per quarter (without biotech included).
Management notes that further acquisitions are on the way and PCAOB auditors are being currently vetted for engagement. With the company’s corporate counsel already being an official OTCQX sponsor, Innovest Global, Inc. (OTC Pink: IVST) is continuing on its path to uplist to higher exchange.
Biotechnology is Innovest Global, Inc.’s (OTC Pink: IVST) latest move to continue building out its holding company platform with high-quality and niche businesses. With a world-renowned neuroscientist tapped to lead the Innovest Biotech subsidiary, the company continues to be on a very successful path.
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand eight hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/